Trial Profile
Safety and efficacy of nivolumab in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Oct 2017 Results (n=109) assessing nivolumab in a real world setting, in heavily pretreated NSCLC patients, were presented at the 18th World Conference on Lung Cancer.
- 25 Oct 2016 New trial record
- 01 Oct 2016 Results published in the Journal of Thoracic Oncology